The World Health Organization has announced the approval for emergency use of the vaccine against Covid-19, Convidecia, of Chinese laboratories CanSino Biologics, as Beijing struggles to deal with a pandemic resurgence.
The vaccine, which is based on a modified human adenovirus, is given in a single dose and is recommended by the WHO for all age groups from the age of 18, the statement said.
The vaccine is 64% effective for the symptomatic form of Covid-19 and 92% against severe forms of the disease.
It is the ninth vaccine against Covid or a variant of the vaccine that receives this valuable WHO approval, which is a seal of quality, efficacy and safety. An important indication for the health authorities of some countries that do not have the means to make a serious evaluation of the preparation themselves.
This approval also allows the international Covax system to use Convidecia on a case-by-case basis for vaccination, especially in poor countries.
China has been called upon in recent months to face an unprecedented pandemic resurgence in the country, where the first cases of Covid-19 were detected in late 2019.
The Omicron variant and its sub-variants are so contagious that they bypass the very strict sanitary measures imposed by the Chinese authorities.
However, under the leadership of President Xi Jinping, the country continues to implement the zero Covid strategy, not hesitating to impose strict quarantine on big cities like Shanghai for example, for several weeks.
The WHO, for its part, says Covid’s “zero tolerance” policy towards Omicron is “unsustainable”.
Follow Skai.gr on Google News
and be the first to know all the news
